We serve Chemical Name:Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI) CAS:173850-53-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI)
CAS.NO:173850-53-8
Synonyms:1-[(3-Methyl-1,2-oxazol-5-yl)methyl]piperazine;Piperazine, 1-[(3-methyl-5-isoxazolyl)methyl]-;1-[(3-methylisoxazol-5-yl)methyl]piperazine;Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI)
Molecular Formula:C9H15N3O
Molecular Weight:181.235
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:298.9±35.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.518
PSA:41.30000
Exact Mass:181.121506
LogP:-0.32
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-[(3-Methyl-1,2-oxazol-5-yl)methyl]piperazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[(3-Methyl-1,2-oxazol-5-yl)methyl]piperazine Use and application,Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI) technical grade,usp/ep/jp grade.
Related News: If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role. Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI) manufacturer Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI) supplier Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI) vendor Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. Piperazine,1-[(3-methyl-5-isoxazolyl)methyl]- (9CI) factory Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations.